Byondis
Norbert Koper is a seasoned professional with extensive experience in clinical development and research. Currently serving as Vice President of Clinical Development at Byondis since May 2020, Koper previously held a similar role at Synthon from November 2010 to April 2020, along with positions as Head of Clinical Operations and Project Leader in Clinical Operations. Prior to this, Koper worked at Medtronic as a Clinical Research Manager in Cardiac Rhythm Disease Management and served as a Senior Clinical Research Scientist at both Schering-Plough and AkzoNobel/Organon. Koper's early career includes a post-doctoral research fellowship in molecular epidemiology and cancer research and consultancy roles at Radboud University Nijmegen Medical Centre in Epidemiology and Biostatistics. Koper holds a Ph.D. in gynecologic oncology and an MSc in Health Sciences with a focus on Epidemiology, both from Radboud University.
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.